Class / Patent application number | Description | Number of patent applications / Date published |
424194100 | Conjugated via claimed linking group, bond, or coupling agent | 84 |
20080233143 | Adjuvanting Material - The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group. | 09-25-2008 |
20080286296 | Cyclic-Dinucleotides and Its Conjugates as Adjuvants and Their Uses in Pharmaceutical Compositions - The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions. | 11-20-2008 |
20080305127 | Conjugate Vaccines - The invention provides vaccines against | 12-11-2008 |
20090047303 | Method for improving the immunogenicity of plasmodium antigens - The present invention provides a Malaria antigen-carrier conjugate, which comprises a carrier protein and a plurality of | 02-19-2009 |
20090092632 | Methods for preparing complex multivalent immunogenic conjugates - Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. | 04-09-2009 |
20090155299 | Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections - The present invention relates to conjugates of oligosaccharides of formula 1, wherein R is a linker to a carrier protein and optionally comprises up to three further saccharides, 5 and which are useful for vaccination, methods of synthesis of such conjugates, antibodies against this antigen, hybridoma producing monoclonal antibodies against this antigen, assays using these antibodies for the detection of | 06-18-2009 |
20090214586 | Combination Vaccines With Whole Cell Pertussis Antigen - Vaccines have been studied that comprise (a) D-T-Pw-HepB-Hib antigens and (b) one or more meningococcal conjugate antigens. A number of improvements and variations of these vaccines have been discovered. The vaccines can be prepared extemporaneously at the time of use by mixing together two components: (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a Hib conjugate and one or more meningococcal conjugates. | 08-27-2009 |
20090232840 | VACCINES AGAINST ESCHERICHIA COLI O157 INFECTION - This invention relates to conjugates of the O-specific polysaccharide of | 09-17-2009 |
20090246221 | IMMUNOMODULATORY AGENTS AND METHODS OF USE - An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, (ii) is capable of uptake by monocytes, lymphocytes, and dendritic cells in a mammalian subject, (iii) contains between 10-40 nucleotide bases, and (iv) has a base sequence effective to hybridize to at least 12 contiguous bases of a target sequence contained in an exon-2 or exon-4 slice site region of human IL-10 pre-mRNA. | 10-01-2009 |
20090263414 | Bifunctional Protein Anchors - The invention relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allows the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, said bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to said carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also provided is a pharmaceutical (e.g. vaccine) composition comprising an antigen-loaded immunogenic carrier complex of the invention. | 10-22-2009 |
20090311285 | VACCINE - The present invention relates to immunogenic compositions or vaccines comprising a Vi capsular saccharide-protein carrier conjugate, methods of making the immunogenic compositions or vaccines and uses thereof. | 12-17-2009 |
20100040644 | METHODS FOR PREPARING IMMUNOGENIC CONJUGATES - Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage. | 02-18-2010 |
20100080820 | Preparation of a Therapeutic Composition - Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm. | 04-01-2010 |
20100119540 | Vaccination Regimen for B-Cell Vaccines - This invention relates to the field of vaccination and treatment or prevention diseases. In particular this invention relates to the treatment or prevention of diseases by inducing hapten-specific antibody responses in a vaccinated subject. The invention further provides a method for prevention or treatment of a disease by inducing hapten-specific antibodies in a subject comprising administering into said subject a composition comprising a virus-like particle of an RNA bacteriophage and at least one hapten linked thereto. | 05-13-2010 |
20100150954 | VACCINES AGAINST INFLUENZA VIRUS - Disclosed are immunogenic conjugates having the general formula: | 06-17-2010 |
20100158937 | METHODS FOR CONJUGATION OF OLIGOSACCHARIDES OR POLYSACCHARIDES TO PROTEIN CARRIERS THROUGH OXIME LINKAGES VIA 3-DEOXY-D-MANNO-OCTULSONIC ACID - Methods for preparing an oligosaccharide-protein carrier immunogenic conjugate or a polysaccharide-protein carrier immunogenic conjugate. The methods include obtaining an oligosaccharide or polysaccharide having a KDO moiety located at the terminal reducing end of the oligosaccharide or polysaccharide that includes a carbonyl functional group; and reacting the carbonyl functional group of the KDO moiety with an aminooxylated protein carrier molecule resulting in a conjugate that includes a covalent oxime bond between the oligosaccharide and the protein carrier or the polysaccharide and the protein carrier. | 06-24-2010 |
20100209448 | SYNTHETIC ANTI-CANDIDA ALBICANS OLIGOSACCHARIDE BASED VACCINES - The present invention provides methods of making and using immunogenic oligosaccharide compositions comprising native O-linked and S-linked oligosaccharides coupled to a protein carrier, wherein the resultant conjugate elicits a protectively immunogenic response. These compositions may be useful in vaccines against pathogenic | 08-19-2010 |
20100239601 | METHOD OF IMMUNIZING HUMANS AGAINST SALMONELLA TYPHI USING A VI-REPA CONJUGATE VACCINE - This invention relates to conjugates of the Vi polysaccharide of | 09-23-2010 |
20100303852 | CONJUGATION PROCESS FOR PNAG AND A CARRIER PROTEIN - The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein. | 12-02-2010 |
20100322959 | IMMUNOGENIC COMPOSITION - The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine group on PNAG to form a PNAG conjugate. Methods of using and processes to make an immunogenic composition are also described. | 12-23-2010 |
20110033493 | VACCINE - The present invention provides a method of immunising a subject comprising the step of administering a composition comprising an antigen and a carbohydrate polymer comprising mannose to a mucosal site of the subject, methods of use of the composition for vaccination and sterilization and use of the composition in manufacturing a medicament. | 02-10-2011 |
20110059121 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS - The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases. | 03-10-2011 |
20110200632 | ADJUVANTING MATERIAL - The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group. | 08-18-2011 |
20110229511 | METHOD OF MODIFYING THE IMMUNE RESPONSE - Methods of neutralising circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs. | 09-22-2011 |
20110262479 | RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS - Two-domain MHC polypeptides useful for manipulation of antigen-specific T-cells are disclosed. These polypeptides include MHC class II-based molecules that comprise covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, and to treat conditions mediated by antigen-specific T-cells. | 10-27-2011 |
20110274713 | ANTIGEN-PRESENTING SCAFFOLDS - The invention relates to compounds having formula (I): Scaffold-[L-(Antigen) | 11-10-2011 |
20110274714 | Broad Spectrum Vaccine Against Non-Typhoidal Salmonella - The present invention is drawn to attenuated | 11-10-2011 |
20110287048 | Antigen Specific Tregs and related compositions, methods and systems - Antigen specific regulatory T cells are described and related compositions, methods and systems. Methods to generate an antigen specific anti-inflammatory regulatory T cell is provided, the method comprising contacting either a T cell or an antigen presenting cell with a zwitterionic polysaccharide conjugated to the antigen for a time and under condition to generate an antigen specific regulatory T cell that is capable of inhibiting a pro-inflammatory response against the antigen. | 11-24-2011 |
20110300173 | Capsule composition for use as immunogen against Campylobacter jejuni - Immunogenic compositions, and method of using the compositions to elicit an immune response against | 12-08-2011 |
20110300174 | CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION - The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): | 12-08-2011 |
20110305723 | Molecular Antigen Array - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses. | 12-15-2011 |
20110318382 | IMMUNOMODULATORY AGENTS AND METHODS OF USE - An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, (ii) is capable of uptake by monocytes, lymphocytes, and dendritic cells in a mammalian subject, (iii) contains between 10-40 nucleotide bases, and (iv) has a base sequence effective to hybridize to at least 12 contiguous bases of a target sequence contained in an exon-2 or exon-4 slice site region of human IL-10 pre-mRNA. | 12-29-2011 |
20120003260 | Solid-Phase and Solution-Phase Synthesis of Glycosylphosphatidylinositol Glycans - One aspect of the present invention relates to solution-phase approaches to GPI synthesis. Another aspect of the present invention relates to key building blocks, and syntheses thereof, useful for GPI assembly. Yet another aspect of the invention relates to an automated method for the synthesis of GPIs and fragments thereof. | 01-05-2012 |
20120034259 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS - The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals. | 02-09-2012 |
20120039926 | Compositions and Methods for Modulating Immunogenic Responses by Activating Dendritic Cells - The conjugated peptide constructs described herein can be used to induce production of dendritic cells that generate cytokines. The vaccine-bearing dendritic cells can be administered to induce T cell mediated immune modulating responses. | 02-16-2012 |
20120076817 | POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES - Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products. | 03-29-2012 |
20120100174 | COMPOSITION COMPRISING SORTASE ANCHORED SURFACE PROTEINS OF STREPTOCOCCUS UBERIS - The present invention provides an immunogenic composition comprising one or more | 04-26-2012 |
20120195922 | METHODS FOR PREPARING COMPLEX MULTIVALENT IMMUNOGENIC CONJUGATES - Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. | 08-02-2012 |
20120258130 | VACCINATION REGIMEN FOR B-CELL VACCINES - This invention relates to the field of vaccination and treatment or prevention diseases. In particular this invention relates to the treatment or prevention of diseases by inducing hapten-specific antibody responses in a vaccinated subject. The invention further provides a method for prevention or treatment of a disease by inducing hapten-specific antibodies in a subject comprising administering into said subject a composition comprising a virus-like particle of an RNA bacteriophage and at least one hapten linked thereto. | 10-11-2012 |
20120294886 | PEPTIDE CONJUGATES FOR SUPPRESSING AN IMMUNE RESPONSE, METHODS OF MAKING AND USES THEREFOR - This application relates to peptide conjugates comprising peptides that suppress or otherwise inhibit an unwanted or undesirable immune response attached to lipid moieties, and methods for suppressing immune responses, including preventing, inhibiting, treating or decreasing unwanted or undesirable immune responses including autoimmune or allergic immune responses using these peptide conjugates. | 11-22-2012 |
20120321658 | IMMUNOGENIC COMPOSITION COMPRISING S. PNEUMONIAE POLYSACCHARIDES CONJUGATED TO CARRIER PROTEINS - The present invention relates to an immunogenic composition comprising at least 2 different | 12-20-2012 |
20130004532 | PROCESS FOR MANUFACTURING VACCINES - The present application discloses an improved method for conducting saccharide—protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed. | 01-03-2013 |
20130039939 | LIPOPEPTIDE- AND LIPOPROTEIN-CONJUGATES AND ITS USE - The present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates. In particular, the present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates comprising a lipid-containing moiety representing an adjuvant moiety, a peptide or protein moiety whereby said peptide or protein moiety represents at least one antigenic structure, the antigen-moiety, and, optionally, a conjugate moiety, preferably a monodisperse polyethyleneglycol unit. | 02-14-2013 |
20130136764 | PREPARATION OF CONJUGATES COMPRISING ADENINE DERIVATIVES AND ALLERGENIC PROTEINS AND THEIR USE FOR SPECIFIC IMMUNOTHERAPY OF ALLENGENIC DISEASES - The present invention refers to the preparation of adenine derivative active esters of formula (I) and use thereof for the preparation of stable conjugates between adenine derivative and allergenic proteins having general structure (II) for the modulation of T | 05-30-2013 |
20130156807 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR - The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma. | 06-20-2013 |
20130295129 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF - Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject. | 11-07-2013 |
20130337004 | POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES - Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products. | 12-19-2013 |
20140004142 | PCSK9 VACCINE | 01-02-2014 |
20140044748 | METHODS FOR PREPARING COMPLEX MULTIVALENT IMMUNOGENIC CONJUGATES - Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. | 02-13-2014 |
20140079728 | ADJUVANTING MATERIAL - The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group. | 03-20-2014 |
20140127255 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV - The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds. | 05-08-2014 |
20140141032 | TEMPO-mediated glycoconjugation of immunogenic composition against Campylobacter jejuni with improved structural integrity and immunogenicity - Immunogenic capsule polysaccharide polymer composition, and its method of producing, with improved structural integrity and immunogenic properties. The invention also relates to a method of using the compositions to elicit an immune response to | 05-22-2014 |
20140141033 | CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS - A conjugated compound of formula Q-Z—R | 05-22-2014 |
20140141034 | TYROSINE LIGATION PROCESS - A process is provided for preparing a conjugate of Formula (I-A) or (I) comprising a polypeptide containing n number of tyrosine units, where n is an integer greater than or equal to 1, dispersed within the amino acid chain | 05-22-2014 |
20140170183 | D-Amino Acid Derivative-Modified Peptidoglycan and Methods of Use Thereof - The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans conjugated to a molecule of interest via a linker. | 06-19-2014 |
20140193453 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS - This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner. | 07-10-2014 |
20140242108 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists - A conjugated compound of Formula I: Q-Z—R | 08-28-2014 |
20140286988 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM - 1H-Imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed. | 09-25-2014 |
20140322258 | POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES - Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products. | 10-30-2014 |
20140377302 | IMMUNOGENIC COMPOSITION - The invention provides immunogenic polysaccharide protein conjugates comprising capsular polysaccharides from | 12-25-2014 |
20150024001 | MOLECULAR MIMIC MUCOSAL AIDS VACCINE - The present invention addresses the problem of providing an AIDS vaccine whereby mucosal immunity can be induced, the immune system can be defended against breakdown by HIV infection, HIV can be prevented from escaping the immune system by being highly mutable, and rapid HIV infection can be prevented. According to the present invention, provided is an AIDS vaccine comprising a hub antigen and a complex of N | 01-22-2015 |
20150044253 | IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example | 02-12-2015 |
20150064212 | PROCESS FOR THE PREPARATION AND USE OF A BIVALENT VACCINE AGAINST MORPHINE-HEROIN ADDICTION - Provided are bivalent immunogenic composition against morphine-heroin addiction comprising a carrier protein (“CP”) and a morphinic product, wherein the CP and the morphinic product are connected by a spacer-linker arm having a total molecular size of 16-21 Å, and methods of using the same. | 03-05-2015 |
20150110833 | MOLECULAR IMPRINTED COLORED SILICA BEADS - Macromolecular imprinted silica particles (“MIP”) in the presence of polymer grafted carbon black are disclosed. The disclosed molecular imprinted beads can detect disease in body fluids. For the silica gel matrix, tetraethyl orthosilicate (TEOS) was used as the backbone monomer and 3-aminopropy/triethoxysilane (APS) as a functional monomer. Carbon black was added to the sol-gel process, yielding black silica particles. Furthermore, sodium dodecyl sulfate (SDS) was used as a structure-directing agent to increase network diffusion of the template. A total of 16 MIPs were synthetized in parallel with variables that evaluate the role of key reactants in the synthesis procedure. Agglomeration tests were performed with all 16 MIPs in the presence of their template, alongside their respective controls using only phosphate buffered saline (“PBS”). Each of the MIPs was evaluated using a novel device capable of simultaneously measuring up to four samples for near infrared transmission. | 04-23-2015 |
20150297692 | Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant - The present invention relates to compositions comprising a construct comprising the Aβ1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. | 10-22-2015 |
20150299337 | GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF - [Problem] The purpose is to provide a compound containing a carrier linker moiety and a physiologically active substance moiety or a salt of the compound, wherein a carrier in the carrier linker moiety is biodegradable and is soluble in water. | 10-22-2015 |
20150328300 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS - This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner. | 11-19-2015 |
20150343054 | Heroin Haptens, Immunoconjugates and Related Uses - The present invention provides novel heroin hapten compounds and heroin immunoconjugates which can be used for in vivo production of antibodies that specifically bind to heroin and its psychoactive metabolites. The invention also provides methods of using vaccines comprising the heroin immunoconjugates in active or passive immunization protocols. The compositions and methods of the invention are useful for prevention and treatment of heroin addiction. | 12-03-2015 |
20160000901 | Compositions and Methods for the Production of Virus-Like Particles - Compositions and methods for synthesizing virus-like particles (VLPs) and methods of use thereof are provided. | 01-07-2016 |
20160015821 | GLYCOTARGETING THERAPEUTICS - Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. | 01-21-2016 |
20160022809 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE - The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label. | 01-28-2016 |
20160022826 | CARBOHYDRATE-MODIFIED GLYCOPROTEINS AND USES THEREOF - The present invention provides immunogenic compounds which stimulate immune responses in a subject. The present invention provides compositions comprising an isolated glycoprotein antigen covalently bound at pre-existing carbohydrate residues present on the glycoprotein to a carbohydrate epitope. The present invention also provides a method to induce an immune response in a subject comprising administering the compounds of the invention. The present invention further provides methods of making the compounds of the invention and methods of using the compounds of the invention to stimulate immune responses to infectious disease agents and tumors. | 01-28-2016 |
20160030541 | METHOD OF MODIFYING THE IMMUNE RESPONSE - Methods of neutralizing circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs. | 02-04-2016 |
20160051667 | CONJUGATION OF STAPHYLOCOCCUS AUREUS TYPE 8 CAPSULAR POLYSACCHARIDES - The invention provides a process for preparing a conjugate of a | 02-25-2016 |
20160058859 | IMMUNOGENIC COMPLEX FOR VACCINATION AND METHOD FOR THE PRODUCTION THEREOF - The present invention is related to an immunogenic complex comprising a polymerized antigen, mannan and a dialdehyde, the composition comprising it and the use thereof as an immune response stimulator and vaccine, useful in the treatment of infectious diseases, neoplasms and allergies. Likewise, the invention relates to the method for obtaining said immunogenic complex, based on the antigen and mannan simultaneous polymerization and conjugation by using a dialdehyde. | 03-03-2016 |
20160067345 | OLIGOSACCHARIDE CONJUGATES AND METHODS OF USE - There is provided a method of detecting in a sample the presence of an anti-M and/or anti-A and/or anti-C/Y anti-body, the method comprising contacting the sample with a diagnostic conjugate provided according to the invention, comprising an oligosaccharide which comprises at least two units of 4,6-dideoxy-4-acylamido-α-pyranose and comprising at least one -(1-3)-link between adjacent 4,6-dideoxy-4-acylamido-α-pyranose units, in which the carbon at position 5 in the pyranose is linked to an R group, where R is independently selected from —CH | 03-10-2016 |
20160074522 | IMMUNITY INDUCER FOR SACCHARIDE ANTIGENS - The present invention provides an immunity inducer and an immunity inducing method using same. The immunity inducer has an immunopotentiation effect on any target oligosaccharide antigen, in particular oligosaccharide antigens included in mammal-derived glycoprotein N-linked sugar chains; is capable of providing a monoclonal antibody having high specificity to and affinity with target oligosaccharide antigens; and has as an effective component thereof a glycolipid including a target oligosaccharide antigen (R) and indicated by general formula (2), or a salt thereof. General formula (2): R—Z—Y—CH(NH—CO—(CH | 03-17-2016 |
20160095936 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF - Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject. | 04-07-2016 |
20160101187 | NONLINEAR SACCHARIDE CONJUGATES - This specification is directed to nonlinear saccharide conjugates that comprise polysaccharides that are linked to at least two peptides that comprise T-cell epitopes and have no conformational B-cell epitopes where one of the peptides is linked to an internal saccharide so that the conjugates have a branched (i.e., nonlinear) structure. The specification also provides methods of manufacturing these conjugates, methods of formulating these conjugates in compositions for use as vaccines and methods of using the compositions to induce an immune response to the capsular saccharide. The specification also provides a new polyepitope carrier peptide comprising the PV1 epitope from polio virus. The new polyepitope carrier peptide can be used in both linear saccharide conjugates as well as the nonlinear saccharide conjugates. | 04-14-2016 |
20160136256 | POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES - Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products. | 05-19-2016 |
20160166704 | Cycloalkyne Derivatized Saccharides | 06-16-2016 |
20160175421 | GLYCAN CONJUGATES AND USE THEREOF | 06-23-2016 |
20160375117 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES - The invention relates to the compositions of synthetic oligo-β-(1→6)-2-amino-2-deoxy-D-glu-copyranosides conjugated to carriers, and methods for making and use same. | 12-29-2016 |
20180021439 | OLIGOSACCHARIDE CONJUGATES AND METHODS OF USE | 01-25-2018 |